News
-
-
PRESS RELEASE
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
Tolebrutinib phase 3 study in NEJM shows delayed disability progression in multiple sclerosis. Potential first therapy targeting immunologic drivers. US priority review ongoing -
-
PRESS RELEASE
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
Rilzabrutinib granted orphan drug designation in the US for warm autoimmune hemolytic anemia and IgG4-related disease, potential use in immune thrombocytopenia. Sanofi's novel BTK inhibitor holds promise for rare diseases -
-
PRESS RELEASE
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
Qfitlia (fitusiran) approved as the first US therapy for hemophilia A or B with or without inhibitors, offering consistent protection with few injections, using unique mechanism to reduce bleeding episodes -
-
PRESS RELEASE
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-ever biologic medicine in Japan for COPD patients based on pivotal phase 3 results in adults with elevated eosinophils, marking a new treatment approach for COPD -
PRESS RELEASE
Sanofi: Disclosure of trading in own shares
-
